Comparative Pharmacology
Head-to-head clinical analysis: LIVTENCITY versus VISTIDE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: LIVTENCITY versus VISTIDE.
LIVTENCITY vs VISTIDE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
LIVTENCITY (maribavir) is an inhibitor of the human cytomegalovirus (CMV) UL97 protein kinase, which is essential for viral DNA replication, encapsidation, and egress of mature virions from the infected cell. By blocking UL97 kinase activity, maribavir inhibits viral replication.
Cidofovir is a nucleotide analogue that inhibits viral DNA polymerase by incorporating into viral DNA and causing chain termination, with selectivity for cytomegalovirus (CMV) DNA polymerase.
200 mg orally once daily with food.
5 mg/kg intravenously once weekly for 2 consecutive weeks, then every other week thereafter.
None Documented
None Documented
Terminal elimination half-life is approximately 20 hours, supporting once-daily dosing for sustained antiviral activity.
Terminal elimination half-life is approximately 1.5-2 hours in patients with normal renal function. In patients with renal impairment, the half-life can extend to 5-10 hours or longer, necessitating dose adjustment based on creatinine clearance.
Primarily hepatobiliary excretion; unchanged drug and metabolites eliminated in feces (86%) and urine (14%).
Primarily renal excretion via glomerular filtration and active tubular secretion. Approximately 90-95% of the dose is excreted unchanged in the urine within 24 hours. Biliary/fecal excretion accounts for <5%.
Category C
Category C
Antiviral
Antiviral